Arbutus Biopharma (ABUS) Net Margin (2009 - 2026)
Arbutus Biopharma recorded quarterly Net Margin of 94.74% in Q1 2026, up 122.47% quarter-over-quarter from 421.6% in Q4 2025, and up 148533.0% year-over-year from N/an in Q1 2025.
Arbutus Biopharma's Net Margin history runs 18 years deep, the most recent figure standing at 94.74% for Q1 2026.
- In Q1 2026, Net Margin rose 148533.0% year-over-year to 94.74%; the TTM figure through Mar 2026 stood at 83.6% (up 127896.0% YoY), while the FY2025 annual figure was 242.77%, up 89027.0% from the prior year.
- Net Margin came in at 94.74% for Q1 2026 at Arbutus Biopharma, up from 421.6% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 94.74% in Q1 2026 to a low of 1472.89% in Q3 2024.
- A 5-year average of 620.58% and a median of 421.6% in 2025 frame the typical range for Net Margin.
- Across the five-year window, Net Margin tumbled 104129 bps in 2024 and soared 148533 bps in 2026, its largest moves.
- Arbutus Biopharma's Net Margin stood at 351.19% in 2022, then slumped by 156 bps to 900.33% in 2023, then rose by 12 bps to 794.09% in 2024, then surged by 47 bps to 421.6% in 2025, then jumped by 122 bps to 94.74% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 94.74%, 421.6%, and 1461.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Arbutus Biopharma | 883.58 Mn | 883.58 Mn | - | 94.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.74% |
| Dec 31, 2025 | -421.60% |
| Sep 30, 2025 | -1,461.25% |
| Jun 30, 2025 | 23.30% |
| Mar 31, 2025 | -1,390.59% |
| Dec 31, 2024 | -794.09% |
| Sep 30, 2024 | -1,472.89% |
| Jun 30, 2024 | -1,146.47% |
| Mar 31, 2024 | -1,165.93% |
| Dec 31, 2023 | -900.33% |
| Sep 30, 2023 | -431.60% |
| Jun 30, 2023 | -367.53% |
| Mar 31, 2023 | -244.34% |
| Dec 31, 2022 | -351.19% |
| Sep 30, 2022 | -295.14% |
| Jun 30, 2022 | -99.66% |
| Mar 31, 2022 | -125.31% |
| Dec 31, 2021 | -682.94% |
| Sep 30, 2021 | -725.90% |
| Jun 30, 2021 | -972.65% |
| Mar 31, 2021 | -927.26% |
| Dec 31, 2020 | -845.14% |
| Sep 30, 2020 | -1,430.20% |
| Jun 30, 2020 | -1,128.27% |
| Mar 31, 2020 | -1,129.38% |
| Dec 31, 2019 | -1,701.73% |
| Sep 30, 2019 | -2,786.51% |
| Jun 30, 2019 | -3,993.42% |
| Mar 31, 2019 | -3,824.15% |
| Dec 31, 2018 | -1,245.29% |
| Sep 30, 2018 | -1,703.84% |
| Jun 30, 2018 | 44.21% |
| Mar 31, 2018 | -1,376.39% |
| Dec 31, 2017 | -1,453.91% |
| Sep 30, 2017 | -168.31% |
| Jun 30, 2017 | -1,756.98% |
| Mar 31, 2017 | -7,926.38% |
| Dec 31, 2016 | -112,151.28% |
| Sep 30, 2016 | -2,531.65% |
| Jun 30, 2016 | -42,071.20% |
| Mar 31, 2016 | -3,272.47% |
| Dec 31, 2015 | -54.08% |
| Sep 30, 2015 | -712.96% |
| Jun 30, 2015 | -432.73% |
| Mar 31, 2015 | -380.26% |
| Dec 31, 2014 | -243.72% |
| Sep 30, 2014 | -149.93% |
| Jun 30, 2014 | -506.13% |
| Mar 31, 2014 | -131.17% |
| Dec 31, 2013 | -307.71% |
| Sep 30, 2013 | -117.88% |
| Jun 30, 2013 | -103.59% |
| Mar 31, 2013 | -136.68% |
| Dec 31, 2012 | -150.65% |
| Sep 30, 2012 | -57.34% |
| Jun 30, 2012 | -70.53% |
| Mar 31, 2012 | -72.52% |
| Dec 31, 2011 | -55.81% |
| Sep 30, 2011 | -39.63% |
| Jun 30, 2011 | -81.68% |
| Mar 31, 2011 | -70.77% |
| Dec 31, 2010 | -30.07% |
| Sep 30, 2010 | -62.16% |
| Jun 30, 2010 | -169.01% |
| Mar 31, 2010 | -168.09% |
| Dec 31, 2009 | -31.63% |
| Sep 30, 2009 | -77.85% |